FDA Approves Azedra (iobenguane I 131) for Rare Adrenal Tumors

July 30, 2018 -- The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news